UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

Healthcare Professionals

Patients

Investors

05 The Legacy Continues: Celebrating Two Decades of the UCB Family Epilepsy Scholarship ProgramTM

Read More Share:

Oct

31 NAYZILAM® (midazolam) Results Published in Epilepsy & Behavior Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

Read More Share:

Sep

05 Announcing the 2023 UCB Family Epilepsy Scholarship Winners

Read More Share:

Aug

17 UCB Partners in Health Economics and Outcomes Research to Evolve Solutions for Seizure Clusters

Read More Share:

Aug

16 How Winners of the UCB Family Epilepsy Scholarship Prepare to Go Back to School

As students and parents prepare for a new school year, there can be a lot of stress – from meeting new teachers and preparing for classes, to financial assistance and making new friends. For people living with epilepsy and their caregivers, the stress and worry surrounding back-to-school preparation is compounded.

Read More Share:

Jun

13 UCB Builds Partnerships with Rare Epilepsy Syndrome Patient Groups

Read More Share:

Mar

28 FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)

Read More Share:

Mar

07 UCB Completes Acquisition of Zogenix, Inc.

Read More Share:

Jan

19 UCB to acquire Zogenix

Read More Share:

Aug

30 UCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Older

Read More Share:

Categories

Archives

Sep

05

The Legacy Continues: Celebrating Two Decades of the UCB Family Epilepsy Scholarship ProgramTM

Oct

31

NAYZILAM® (midazolam) Results Published in Epilepsy & Behavior Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

Sep

05

Announcing the 2023 UCB Family Epilepsy Scholarship Winners

Aug

17

UCB Partners in Health Economics and Outcomes Research to Evolve Solutions for Seizure Clusters

Aug

16

How Winners of the UCB Family Epilepsy Scholarship Prepare to Go Back to School

Jun

13

UCB Builds Partnerships with Rare Epilepsy Syndrome Patient Groups

Mar

28

FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)

Mar

07

UCB Completes Acquisition of Zogenix, Inc.

Jan

19

UCB to acquire Zogenix

Aug

30

UCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Older

Choose Country

UCB in the U.S.

Innovation

Disease Areas

Sustainability

Newsroom

Contact

Categories

Archives

Sep

05

The Legacy Continues: Celebrating Two Decades of the UCB Family Epilepsy Scholarship ProgramTM

Oct

31

NAYZILAM® (midazolam) Results Published in Epilepsy & Behavior Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

Sep

05

Announcing the 2023 UCB Family Epilepsy Scholarship Winners

Aug

17

UCB Partners in Health Economics and Outcomes Research to Evolve Solutions for Seizure Clusters

Aug

16

How Winners of the UCB Family Epilepsy Scholarship Prepare to Go Back to School

Jun

13

UCB Builds Partnerships with Rare Epilepsy Syndrome Patient Groups

Mar

28

FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)

Mar

07

UCB Completes Acquisition of Zogenix, Inc.

Jan

19

UCB to acquire Zogenix

Aug

30

UCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Older

Choose Country

UCB in the U.S.

Innovation

Disease Areas

UCB Worldwide

Sustainability

Newsroom

Contact